Idorsia Company Profile
✉ Email this page to a colleague
What is the competitive landscape for IDORSIA, and when can generic versions of IDORSIA drugs launch?
IDORSIA has one approved drug.
There are three US patents protecting IDORSIA drugs.
There are seventy-four patent family members on IDORSIA drugs in thirty-three countries and five supplementary protection certificates in five countries.
Summary for Idorsia
| International Patents: | 74 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Idorsia
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | 10,023,560 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | 9,732,075 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | 9,732,075 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | 9,790,208 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Idorsia Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Philippines | 12014502540 | ⤷ Try a Trial |
| Taiwan | I636982 | ⤷ Try a Trial |
| South Korea | 20160088439 | ⤷ Try a Trial |
| South Korea | 101689093 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Idorsia Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2855453 | LUC00279 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: DARIDOREXANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE CHLORHYDRATE DE DARIDOREXANT; AUTHORISATION NUMBER AND DATE: EU 1/22/1638 20220502 |
| 2855453 | PA2022518 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: DARIDOREKSANTAS; REGISTRATION NO/DATE: 1/22/1638/001-006 20220429 |
| 2855453 | 2022C/543 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DARIDOREXANT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORHYDRATE DE DARIDOREXANT; AUTHORISATION NUMBER AND DATE: EU/1/22/1638 20220502 |
| 2855453 | 301197 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DARIDOREXANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER DARIDOREXANTHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1638 20220502 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
